Literature DB >> 24347506

Association of serum uric acid and incident nonspine fractures in elderly men: the Osteoporotic Fractures in Men (MrOS) study.

Nancy E Lane1, Neeta Parimi, Li-Yung Lui, Barton L Wise, Wei Yao, Yu-An Evan Lay, Peggy M Cawthon, Eric Orwoll.   

Abstract

Uric acid (UA) is produced from purines by the enzyme xanthine oxidase, and elevated levels may cause arthritis and kidney stones. Conversely, UA also appears to function as an antioxidant and may protect against the oxidative stress associated with aging and disease. We performed a prospective fracture case-cohort study to understand the relation of UA and fracture risk in older men enrolled in the Osteoporotic Fractures in Men (MrOS) study. In the cohort of 5994 men aged 65 years and older attending the baseline MrOS examination, we evaluated a subgroup 1680 men in a case-cohort study design. The analytic group included 387 men with incident nonspine fractures (73 hip) and a random sample of 1383. Serum UA was measured in baseline serum samples. Modified proportional hazards models that account for case-cohort study design were used to estimate the relative hazards (RH) of hip and nonspine fracture in men for serum UA. Models were adjusted for age, race, clinic site, body mass index, vitamin D, parathyroid hormone, walking speed, Physical Activity Scale for the Elderly (PASE) score, frailty, and total. Subjects with incident nonspine fractures were older, had lower total hip bone mineral density (BMD), and higher serum phosphorus. There was an 18% decreased risk of nonspine fractures (95% confidence interval [CI] 0.71-0.93; p = 0.003) per 1 SD increase of baseline serum and 34% decreased risk of nonspine fractures in quartile 4 of UA versus quartiles 1, 2, and 3 (95% CI 0.49-0.89; p = 0.028) compared with nonfracture cases after multivariate adjustment. Hip fractures were not significantly associated with UA. Total hip BMD was significantly higher in the group of men with high UA levels compared with lower UA levels and increased linearly across quartiles of UA after multivariate adjustment (p for trend = 0.002). In summary, higher serum UA levels were associated with a reduction in risk of incident nonspine fractures but not hip fractures and higher hip BMD.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  AGING; DXA < ANALYSIS/QUANTITATION OF BONE; EPIDEMIOLOGY

Mesh:

Substances:

Year:  2014        PMID: 24347506      PMCID: PMC4351860          DOI: 10.1002/jbmr.2164

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  40 in total

1.  Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease.

Authors:  Wenzhen Duan; Bruce Ladenheim; Roy G Cutler; Inna I Kruman; Jean Lud Cadet; Mark P Mattson
Journal:  J Neurochem       Date:  2002-01       Impact factor: 5.372

2.  Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study.

Authors:  Dario Maggio; Mauro Barabani; Marco Pierandrei; M Cristina Polidori; Marco Catani; Patrizia Mecocci; Umberto Senin; Roberto Pacifici; Antonio Cherubini
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

3.  Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease.

Authors:  S Spitsin; D C Hooper; T Leist; L J Streletz; T Mikheeva; H Koprowskil
Journal:  Mult Scler       Date:  2001-10       Impact factor: 6.312

4.  [Parathyroid function and uric acid metabolism].

Authors:  M Yoneda; K Takatsuki; A Tomita
Journal:  Nihon Naibunpi Gakkai Zasshi       Date:  1983-11-20

5.  Frailty in older adults: evidence for a phenotype.

Authors:  L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-03       Impact factor: 6.053

6.  Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors.

Authors:  Gwen S Scott; Sergei V Spitsin; Rhonda B Kean; Tatiana Mikheeva; Hilary Koprowski; D Craig Hooper
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-25       Impact factor: 11.205

7.  Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System.

Authors:  E J Erlandsen; E Randers; J H Kristensen
Journal:  Scand J Clin Lab Invest       Date:  1999-02       Impact factor: 1.713

8.  Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment.

Authors:  S Valdemarsson; P Lindblom; A Bergenfelz
Journal:  J Intern Med       Date:  1998-09       Impact factor: 8.989

9.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.

Authors:  B N Ames; R Cathcart; E Schwiers; P Hochstein
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

10.  Antioxidant status in patients with osteoporosis: a controlled study.

Authors:  Omer Faruk Sendur; Yasemin Turan; Engin Tastaban; Mukadder Serter
Journal:  Joint Bone Spine       Date:  2009-05-21       Impact factor: 4.929

View more
  25 in total

1.  Serum uric acid is associated with quantitative ultrasound parameters in men: data from the Camargo cohort.

Authors:  J L Hernández; D Nan; J Martínez; E Pariente; I Sierra; J González-Macías; J M Olmos
Journal:  Osteoporos Int       Date:  2015-03-03       Impact factor: 4.507

2.  Bone microstructure and volumetric bone mineral density in patients with hyperuricemia with and without psoriasis.

Authors:  D Simon; J Haschka; C Muschitz; A Kocijan; A Baierl; A Kleyer; G Schett; S Kapiotis; H Resch; M Sticherling; J Rech; R Kocijan
Journal:  Osteoporos Int       Date:  2020-01-10       Impact factor: 4.507

3.  Gout and Risk of Fracture in Women: A Prospective Cohort Study.

Authors:  Julie M Paik; Seoyoung C Kim; Diane Feskanich; Hyon K Choi; Daniel H Solomon; Gary C Curhan
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

4.  Positive association between serum uric acid and bone mineral density in Chinese type 2 diabetes mellitus stratified by gender and BMI.

Authors:  Mingxin Xu; Junlei Su; Jie Hao; Ni Zhong; Zhiyin Zhang; Ran Cui; Feng Li; Chunjun Sheng; Ge Zhang; Hui Sheng; Shen Qu
Journal:  J Bone Miner Metab       Date:  2017-11-09       Impact factor: 2.626

Review 5.  The association between serum uric acid level and the risk of fractures: a systematic review and meta-analysis.

Authors:  P Yin; H Lv; Y Li; Y Meng; L Zhang; P Tang
Journal:  Osteoporos Int       Date:  2017-05-09       Impact factor: 4.507

6.  Relationship between serum uric Acid and bone mineral density in the general population and in rats with experimental hyperuricemia.

Authors:  Dihua Zhang; I Alexandru Bobulescu; Naim M Maalouf; Beverley Adams-Huet; John Poindexter; Sun Park; Fuxin Wei; Christopher Chen; Orson W Moe; Khashayar Sakhaee
Journal:  J Bone Miner Res       Date:  2015-06       Impact factor: 6.741

7.  Serum urate levels and the risk of hip fractures: data from the Cardiovascular Health Study.

Authors:  Tapan Mehta; Petra Bůžková; Mark J Sarnak; Michel Chonchol; Jane A Cauley; Erin Wallace; Howard A Fink; John Robbins; Diana Jalal
Journal:  Metabolism       Date:  2014-11-21       Impact factor: 8.694

8.  Higher serum uric acid is associated with higher lumbar spine bone mineral density in male health-screening examinees: a cross-sectional study.

Authors:  Jiwon Hwang; Jung Hye Hwang; Seungho Ryu; Joong Kyong Ahn
Journal:  J Bone Miner Metab       Date:  2018-01-25       Impact factor: 2.626

9.  Gout and the Risk of Non-vertebral Fracture.

Authors:  Seoyoung C Kim; Julie M Paik; Jun Liu; Gary C Curhan; Daniel H Solomon
Journal:  J Bone Miner Res       Date:  2016-09-06       Impact factor: 6.741

Review 10.  Osteoporosis in men: findings from the Osteoporotic Fractures in Men Study (MrOS).

Authors:  Peggy M Cawthon; Mohammad Shahnazari; Eric S Orwoll; Nancy E Lane
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-02       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.